• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomeTeam

August 6, 2024 by

Peter Thompson, M.D., serves as a member of our board of directors and is a Partner on the private equity team at OrbiMed, with over 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded Corvus Pharmaceuticals, Cleave Biosciences, Silverback Therapeutics and serves as a director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

August 6, 2024 by

Laura Brege serves as a member of our board of directors and is a Senior Advisor at BridgeBio Pharma (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to joining BridgeBio Pharma, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From 2012 to 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused in oncology and immunology. Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. (acquired by Amgen) from 2006 to 2011 including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege serves on the boards of Acadia Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., and HLS Therapeutics, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.

August 6, 2024 by

Badreddin Edris, Ph.D., is a co-founder of Edgewise Therapeutics and serves as a member of our board of directors after having served as our strategic advisor and in an operational role. Dr. Edris is currently the Chief Operating Officer of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on rare diseases and cancer. At SpringWorks, Dr. Edris leads the company’s strategic planning, business development, capital formation, investor relations, and competitive intelligence efforts. Prior to joining SpringWorks, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. In addition to Edgewise, Dr. Edris also co-founded Silverback Therapeutics while at OrbiMed and served as the company’s Chief Business Officer. Before OrbiMed, Dr. Edris was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects. Dr. Edris received his Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.

August 6, 2024 by

Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.

August 6, 2024 by

Kevin Koch, Ph.D., has served as our President, Chief Executive Officer and a member of our board of directors since 2017 and has been in the life science industry for over 30 years with a focus on drug discovery, translational medicine and clinical development. Since 2016, he has also served as a Venture Partner with OrbiMed. Dr. Koch previously served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen where he managed global drug discovery and biomarker development. Dr. Koch was a co-founder of Array BioPharma, serving as President, Chief Scientific Officer and board member from the company’s inception in 1998 to 2013. While there, he built a fully integrated research and development team that oversaw the invention of over 20 clinical development candidates across multiple therapeutic areas, several of which are now marketed medicines. Prior to Array, Dr. Koch held senior positions at Amgen and Pfizer Central Research. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Synthetic Organic Chemistry from University of Rochester.

August 6, 2024 by

Arlene Morris serves as a member of our board of directors and is Chief Executive Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy, and business development. She brings extensive experience in the pharmaceutical and biotechnology industries from numerous management and board roles. Previously, she spent over a decade leading public biotechnology companies, as Chief Executive Officer of Syndax Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and prior, as President and Chief Executive Officer of Affymax, where she led the company through the development of peginesatide (Omontys®). Ms. Morris also held various management and executive positions at Clearview Projects, Coulter Pharmaceutical, Scios, and Johnson & Johnson. She is currently a member of the Board of Directors of Cogent Biosciences, Palatin Technologies, TC BioPharm and Viridian Therapeutics.

  • Page 1
  • Page 2
  • Page 3
  • Next

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts